Copyright
©The Author(s) 2022.
World J Hepatol. Mar 27, 2022; 14(3): 602-611
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.602
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.602
Table 3 End of treatment biopsy compared to follow up biopsy
| Patient number | End of treatment biopsy | Weeks between both biopsies | ALT | Follow up biopsy | ||
| Inflammation | Fibrosis | Inflammation | Fibrosis | |||
| 3 | 2 | 0 | 38 | 20 | 1 ↓ | 0 ↔ |
| 4 | 3 | 0 | 42 | 15 | 2 ↓ | 1 ↑ |
| 5 | 1 | 3 | 43 | 20 | 2 ↑ | 3 ↔ |
| 10 | 4 | 3 | 48 | 22 | 2 ↓ | 3↔ |
| 11 | 4 | 2 | 44 | 71 | 3 ↓ | 3 ↑ |
- Citation: Ismail B, Benrajab KM, Bejarano P, Ruiz P, Sears D, Tzakis A, Zervos XB. Benign course of residual inflammation at end of treatment of liver transplant recipients after sofosbuvir based therapy. World J Hepatol 2022; 14(3): 602-611
- URL: https://www.wjgnet.com/1948-5182/full/v14/i3/602.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i3.602